For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed al ...

Core Viewpoint - Veracyte, Inc. is actively engaging with investors through participation in notable conferences, indicating a focus on enhancing investor relations and visibility in the cancer diagnostics sector [1] Group 1: Conference Participation - The company will present at the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on March 3rd at 8:05 a.m. Eastern Time [1] - Veracyte will also participate in a fireside chat at the Leerink Partners Global Health Conference in Miami, FL on March 9th at 10:40 a.m. Eastern Time [1] - Live audio webcasts of the company's presentations will be available, allowing broader access to their discussions [1]

Core Insights - Veracyte, Inc. (VCYT) is set to report its fourth-quarter 2025 results on February 25, with expectations of strong performance based on previous earnings surprises [1][9] Financial Performance - The Zacks Consensus Estimate for revenues is $138.7 million, indicating a 16.9% increase from the previous year [2] - The Zacks Consensus Estimate for EPS is 41 cents, reflecting a 13.9% year-over-year growth [2] - Earnings estimates have increased by 2.5% in the last 30 days, suggesting positive sentiment leading up to the earnings report [3] Business Segments - The core testing business is anticipated to show solid revenue growth, driven by strong volumes in Decipher and Afirma tests [4][9] - Decipher Prostate tests delivered approximately 26,700 tests in the third quarter, marking 14 consecutive quarters of over 25% year-over-year volume growth, a trend expected to continue [5] - Test volumes in the high-risk localized segment are also expected to have increased, supported by ongoing research and clinical adoption [6] Product Insights - Product volume in the third quarter was around 2,200 tests, with a year-over-year revenue growth of 4%, a trend expected to persist [7] - However, management has indicated a decline in product gross margin due to a transition to a contract manufacturing model [7][9] Market Position - VCYT has an Earnings ESP of +7.98% and a Zacks Rank of 2 (Buy), indicating a higher likelihood of beating earnings estimates [11] - The company is facing challenges in its biopharma revenues and expects lower product gross margins in the fourth quarter due to restructuring efforts [9][10]

Core Viewpoint - Veracyte (VCYT) has experienced a significant downtrend, with a 20% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - VCYT's current RSI reading is 28.44, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - Analysts covering VCYT have shown strong consensus in raising earnings estimates, with a 0.8% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - VCYT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Core Viewpoint - Veracyte, Inc. is set to release its financial results for the fourth quarter and full year of 2025 on February 25, 2026, and anticipates significant revenue growth compared to the previous year [1]. Financial Results - For the fourth quarter of 2025, Veracyte expects total revenue to be between $138 million and $140 million, reflecting an increase of 16% to 18% compared to the same period in 2024 [1]. Upcoming Events - The company will host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update [1]. - Veracyte will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 9:45 a.m. Pacific Time [1]. - The company is also scheduled to participate in the Wolfe Research Healthcare Conference and the Jefferies Global Healthcare Conference in November 2025 [1].

Core Viewpoint - Veracyte (VCYT) has experienced a bearish trend recently, losing 11.6% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1] Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which supports a bullish outlook for the stock [2] - A hammer pattern forms when there is a small difference between opening and closing prices, with a long lower wick, signaling that bears may be losing control [4][5] - The occurrence of a hammer pattern at the bottom of a downtrend suggests that bulls may have successfully halted further price declines, indicating a potential trend reversal [5] Fundamental Analysis - There has been a recent upward trend in earnings estimate revisions for VCYT, which is a bullish indicator as it typically leads to price appreciation [7] - The consensus EPS estimate for the current year has increased by 0.8% over the last 30 days, indicating strong agreement among analysts regarding improved earnings potential [8] - VCYT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which historically outperforms the market [9][10]

Core Insights - Veracyte (VCYT) is positioned to continue its earnings-beat streak, having surpassed earnings estimates by an average of 50.66% in the last two quarters [1] Earnings Performance - In the last reported quarter, Veracyte achieved earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, resulting in a surprise of 59.38% [2] - In the previous quarter, the company was expected to report earnings of $0.31 per share but delivered $0.44 per share, leading to a surprise of 41.94% [2] Earnings Estimates and Predictions - Recent estimates for Veracyte have been trending upward, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better historically results in a positive surprise nearly 70% of the time [6] Earnings ESP Analysis - Veracyte currently has an Earnings ESP of +7.98%, suggesting increased analyst optimism regarding its near-term earnings potential [8] - The positive Earnings ESP, combined with a Zacks Rank of 1 (Strong Buy), indicates a high probability of another earnings beat [8]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned to profit from the surge in electricity demand driven by AI data centers [3][6] Market Position - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from American LNG exports and benefiting from the onshoring trend due to tariffs [5][6] - It possesses a unique footprint in nuclear energy, which is crucial for America's future power strategy, and is capable of executing large-scale engineering projects across various energy sectors [7][8] Financial Health - The company is noted for being completely debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth engines without the associated premium costs [9][10] Market Sentiment - There is a growing interest from hedge funds in this company, which is considered undervalued and off-the-radar, trading at less than 7 times earnings excluding cash and investments [10][11] - The company is recognized for delivering real cash flows and owning critical infrastructure, making it an attractive investment opportunity in the context of the AI revolution [11][12]

Core Insights - The article discusses the potential of mid-cap stocks as attractive investment opportunities, particularly in the context of the "America First" agenda which aims to boost domestic manufacturing [2][3]. Industry Overview - The U.S. stock market is experiencing a shift with a growing interest in mid-cap stocks, which are expected to benefit from domestic revenue generation [2]. - Historically, mid-cap equities have outperformed both large-cap and small-cap stocks, although they have lagged behind large caps in the current year [3]. Hedge Fund Activity - Hedge funds are reportedly rotating out of large-cap stocks, with significant reductions in exposure to mega-cap stocks noted in Q3 2025 [4]. - Major hedge funds, such as Bridgewater Associates, have cut holdings in prominent stocks while increasing investments in mid-cap companies [4]. Methodology for Stock Selection - The article outlines a methodology for selecting high-growth mid-cap stocks, focusing on companies with market capitalizations between $2 billion and $10 billion and at least 30% revenue growth over five years [6]. Featured High-Growth Mid-Cap Stocks - **LifeStance Health Group, Inc. (NASDAQ:LFST)** - Market Capitalization: $2.82 billion - Revenue Growth (5Y): 36.75% - Analysts have raised price targets for LFST, indicating a positive outlook despite industry challenges [9][10][11][12]. - **Veracyte, Inc. (NASDAQ:VCYT)** - Market Capitalization: $3.29 billion - Revenue Growth (5Y): 34.46% - The company forecasts sales of $570 million to $582 million in 2026, exceeding consensus estimates [13][14][15]. - **Kinsale Capital Group, Inc. (NYSE:KNSL)** - Market Capitalization: $9.28 billion - Revenue Growth (5Y): 34.25% - Analysts have mixed views, with one firm initiating coverage with an Overweight rating while another lowered its price target due to anticipated near-term declines [16][17][18][19].

Core Viewpoint - The bullish perspective on Veracyte (VCYT) is grounded in the company's current financial performance rather than mere optimism about future technologies [1] Group 1: Company Performance - Veracyte has successfully transitioned out of previous phases, indicating a positive shift in its operational strategy [1] - The company is positioned in high-growth sectors that are expected to experience exponential expansion [1] Group 2: Investment Strategy - The investment approach focuses on fundamental analysis combined with predictions of future trends, emphasizing the potential of innovation to generate substantial returns [1]